Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465817 | 0.94 | CYP19A1 (0.57) | HAO1CYP19A1ALDH1A1SMN1; SMN2GRM5 | |
| SCHEMBL4454767 | 0.90 | CYP19A1 (0.63) | HAO1CYP19A1ALDH1A1SMN1; SMN2GRM5 | |
| SCHEMBL4458288 | 0.86 | FFAR4 (0.53) | HAO1CYP19A1ALDH1A1SMN1; SMN2GRM5 | |
| SCHEMBL4459762 | 0.85 | LMNA (0.47) | HAO1CYP19A1ALDH1A1SMN1; SMN2GRM5 | |
| SCHEMBL4465810 | 0.85 | CYP19A1 (0.47) | HAO1CYP19A1ALDH1A1GRM5LMNA | |
| SCHEMBL4466680 | 0.84 | CYP19A1 (0.55) | HAO1CYP19A1ALDH1A1SMN1; SMN2GRM5 | |
| SCHEMBL13606234 | 0.83 | CYP19A1 (0.53) | CYP19A1ALDH1A1SMN1; SMN2GRM5LMNA | |
| SCHEMBL12562322 | 0.83 | CYP19A1 (0.71) | CYP19A1ALDH1A1SMN1; SMN2GRM5LMNA | |
| SCHEMBL13606342 | 0.81 | CYP19A1 (0.57) | CYP19A1ALDH1A1SMN1; SMN2GRM5LMNA | |
| SCHEMBL13989096 | 0.81 | FFAR4 (0.48) | HAO1CYP19A1ALDH1A1SMN1; SMN2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306115-A1 | Phenyl ethyne compounds | MERCK SHARP & DOHME CORP. | 2009-12-10 | — | — | US | disclosed |
| US-20090306115-A1 | Phenyl ethyne compounds | MERCK SHARP & DOHME CORP. | 2009-12-10 | — | — | US | disclosed |
| US-20090306115-A1 | Phenyl ethyne compounds | MERCK SHARP & DOHME CORP. | 2009-12-10 | — | — | US | disclosed |
| EP-1874724-A2 | PHENYL ETHYNE COMPOUNDS | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006115895-A2 | PHENYL ETHYNE COMPOUNDS | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306115-A1 | Phenyl ethyne compounds | DDT, CHRM3, CBR3 | HAO1 3171/4885CYP19A1 583/4885ALDH1A1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.